A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients.
assisted reproductive technology
breast cancer
controlled ovarian stimulation
cryopreservation
oncofertility
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
22
02
2019
accepted:
10
07
2019
pubmed:
1
8
2019
medline:
3
3
2020
entrez:
1
8
2019
Statut:
ppublish
Résumé
The survival rates of cancer patients have greatly improved owing to the advances in oncology. The preservation of fertility in cancer patients is an important task. To determine the reality of cryopreservation of embryos, oocytes and ovarian tissue in cancer patients, large-scale survey analysis was performed in Japan. We sent 613 Japan Society of Obstetrics and Gynecology-certified assisted reproductive technology institutions a questionnaire about their experience of performing cryopreservation for cancer patients between January 2011 and December 2015. Subsequently, the institutions that conducted cryopreservation for cancer patients were sent a second questionnaire. We received replies from 481 (78.5%) institutions. Among them, 126 (26.2%) conducted cryopreservation for cancer patients. These 126 institutions were sent a second questionnaire. Of these, 108 (85.7%) institutions responded. At the 108 institutions, 1085 embryo or oocyte cryopreservation procedures and 122 ovarian tissue cryopreservation procedures were conducted for cancer patients. Cryopreservation was mainly performed for breast cancer patients (~70%), followed by patients with hematological malignancy. A total of 361 and 19 embryo transfer cycles were performed for patients whose embryos and oocytes were cryopreserved, respectively, and 42 and seven institutions reported pregnancy outcomes after embryo transfer in patients that underwent embryo and oocyte cryopreservation, respectively. However, pregnancy was not observed in the seven cases that underwent ovarian tissue transfer. Indications, age limits and ovarian stimulation protocols for cryopreservation widely varied between the institutions. A national registration system for oncofertility must be established to evaluate the safety and efficacy of the current system.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2021-2028Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 18ck0106230h0003
Informations de copyright
© 2019 Japan Society of Obstetrics and Gynecology.
Références
Smith JR, Boyle DC, Corless DJ et al. Abdominal radical trachelectomy: A new surgical technique for the conservative management of cervical carcinoma. Br J Obstet Gynaecol 1997; 104: 1196-1200.
Kajiyama H, Shibata K, Suzuki S et al. Fertility-sparing surgery in young women with invasive epithelial ovarian cancer. Eur J Surg Oncol 2010; 36: 404-408.
Satoh T, Hatae M, Watanabe Y et al. Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: A proposal for patient selection. J Clin Oncol 2010; 28: 1727-1732.
Harada M, Osuga Y. Fertility preservation for female cancer patients. Int J Clin Oncol 2018; 24: 28-33.
Cakmak H, Rosen MP. Ovarian stimulation in cancer patients. Fertil Steril 2013; 99: 1476-1484.
Grynberg M, Poulain M, le Parco S, Sifer C, Fanchin R, Frydman N. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients. Hum Reprod 2016; 31: 623-629.
von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B. Fertility preservation in women--a practical guide to preservation techniques and therapeutic strategies in breast cancer, Hodgkin's lymphoma and borderline ovarian tumours by the fertility preservation network FertiPROTEKT. Arch Gynecol Obstet 2011; 284: 427-435.
Reddy J, Oktay K. Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertil Steril 2012; 98: 1363-1369.
Kim J, Turan V, Oktay K. Long-term safety of letrozole and gonadotropin stimulation for fertility preservation in women with breast cancer. J Clin Endocrinol Metab 2016; 101: 1364-1371.
Loren AW, Mangu PB, Beck LN et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2500-2510.
Bastings L, Beerendonk CC, Westphal JR et al. Autotransplantation of cryopreserved ovarian tissue in cancer survivors and the risk of reintroducing malignancy: A systematic review. Hum Reprod Update 2013; 19: 483-506.
Dolmans MM, Luyckx V, Donnez J, Andersen CY, Greve T. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril 2013; 99: 1514-1522.
Dolmans MM. Recent advances in fertility preservation and counseling for female cancer patients. Expert Rev Anticancer Ther 2018; 18: 115-120.
Dolmans MM, Manavella DD. Recent advances in fertility preservation. J Obstet Gynaecol Res 2019; 45: 266-279.
Diaz-Garcia C, Domingo J, Garcia-Velasco JA et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: A prospective cohort study. Fertil Steril 2018; 109: 478-485.